Product Description: Mirdametinib (PD0325901) is an orally active, selective and non-ATP-competitive MEK inhibitor with an IC50 of 0.33 nM. Mirdametinib exhibits a Kiapp of 1 nM against activated MEK1 and MEK2. Mirdametinib suppresses the expression of p-ERK1/2 and induces apoptosis. Mirdametinib has anti-cancer activity for a broad spectrum of human tumor xenografts[1][2][3].
Applications: Cancer-Kinase/protease
Formula: C16H14F3IN2O4
References: [1]Barrett SD, et al. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6501-4./[2]Henderson YC, et al. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol Cancer Ther. 2010 Jul;9(7):1968-76./[3]Judith S. Sebolt-Leopold, et al. The biological profile of PD 0325901: A second generation analog of CI-1040 with improved pharmaceutical potential
CAS Number: 391210-10-9
Molecular Weight: 482.19
Compound Purity: 99.95
Research Area: Cancer
Solubility: DMSO : ≥ 56 mg/mL
Target: Apoptosis;Autophagy;MEK
English
Deutsch
